LumiThera Named Most Promising and Innovative Catalyzer Startup at BIOVISION 2016

SEATTLE, April 27, 2016 /PRNewswire/ -- LumiThera ® Inc., a late-stage developmental medical device company creating a non-invasive photobiomodulation (PBM) treatment for ocular disorders and disease, today announced it has been awarded the prestigious "MOST PROMISING AND INNOVATIVE CATALYZER AWARD" during Biovision 2016, Lyon, France.

Biovision is a high-level investor event connecting industrial partners, financial investors and the best medical technology, biotechnology, and e-health start-up and mid-size companies, http://www.biovision.org. The most promising companies in each category are awarded based upon key criteria such as societal benefit, market attractiveness, innovative approach, competitive position, team structure and attractiveness for investment.

LumiThera is commercializing the LumiThera LT-300 LED medical device for the ophthalmic community. Currently, the only treatment for dry AMD is vitamin supplements. The LumiThera LT-300 is a non-invasive, non-pharmaceutical photobiomodulation (PBM) approach to a previously untreated population of dry AMD patients.

Two clinical studies have demonstrated clinical and pathological benefits in subjects. Early adopters have been identified and the company is establishing first in class data to support the proposed claims and commercialization.

"We are delighted that BIOVISION has recognized the innovation and business attractiveness of LumiThera,"  said Clark Tedford, Ph.D., Chief Executive Officer." The innovative and elegant design of the LumiThera LT-300 offers the potential to provide treatment to this currently underserved population and by doing so improve their quality of life."

About Age Related Macular Degeneration (AMD)

Age-related macular degeneration (AMD) accounts for 8.7% of all blindness worldwide and is the most common cause of blindness according to the World Health Organization. Disease prevalence is likely to increase due to population aging. Approximately, 85-90% of AMD is the "dry" form of the disease. The emotional and socioeconomic impact of AMD is large because vision impairment caused by the disease, which primarily affects central (straight-on) rather than peripheral (side) vision can severely impact daily activities such as reading and driving.

About LumiThera Inc.

LumiThera, Inc. is a developmental-stage medical device company focused on treating patients affected by dry age-related macular degeneration. The Company's expertise is in the application of photobiomodulation ("PBM"), using non-invasive light emitting diodes ("LED") and laser treatments for acute and chronic ocular diseases and disorders. The Company is developing an ophthalmic LED office-based instrument to be used in multiple ocular conditions or disorders as non-invasive medical treatments.

The LT-300 is currently in clinical trials and is not CE Marked nor FDA 510K Cleared.

2016 LumiThera Inc., All rights reserved.

Visit the Company's website at www.lumithera.com.

SOURCE LumiThera Inc.

Related Links

http://www.lumithera.com